Figure 1. Increased NK cell cytotoxicity against UCLA-OSCSCs.

PBMCs and NK cells were left untreated or treated with IL-2 (1000 units/ml) or anti-CD16 mAb (3µg/ml) or a combination of IL-2 (1000 units/ml) and anti-CD16 mAb (3µg/ml) for 12–24 hours before they were added to ⁵¹Cr labeled primary oral tumors. PBMC (A) and NK cell (B) cytotoxicities were determined using a standard ⁵¹Cr release assay and the lytic units 30/10⁶ cells were calculated using inverse number of effectors required to lyse 30% of the tumor cells ×100. Differences between untreated, anti-CD16 mAb treated or IL-2 and/or anti-CD16 mAb treated NK cell cytotoxicity between UCLA-OSCCs and UCLA-OSCSCs were significant at a p value of <0.05. One of four representative experiments is shown in this figure.